<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959762</url>
  </required_header>
  <id_info>
    <org_study_id>931430</org_study_id>
    <secondary_id>16GRNT31090037</secondary_id>
    <nct_id>NCT02959762</nct_id>
  </id_info>
  <brief_title>Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)</brief_title>
  <official_title>Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Animal studies have found that vitamin K-dependent proteins matrix Gla protein and
      osteocalcin beneficially influence lipid and glucose metabolism, respectively. However, this
      concept has not been tested in humans at risk for dyslipidemia and diabetes risk. Vitamin K
      supplementation presents an opportunity to test the hypothesized link between the vitamin
      K-dependent proteins and markers of lipid and glucose metabolism. The investigators will
      conduct an 8-week vitamin K intervention (to manipulate carboxylation of matrix Gla protein
      and osteocalcin) and determine its effects on markers of dyslipidemia and diabetes risk.
      Sixty obese children will be randomly allocated to either the control group receiving placebo
      or the low-dose (45 mcg/d) or high-dose group (90 mcg/d) receiving vitamin K (menaquinone-7).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum lipid concentrations</measure>
    <time_frame>8 weeks</time_frame>
    <description>To determine if the vitamin K-induced change in matrix Gla protein carboxylation improves fasting lipid panel (triglycerides, total cholesterol, HDL-cholesterol, and LDL-cholesterol) in a dose-dependent manner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>8 weeks</time_frame>
    <description>To determine if the vitamin K-induced change in osteocalcin carboxylation effects insulin sensitivity in a dose-dependent manner. Insulin sensitivity will be calculated from plasma insulin and glucose concentrations measured during a two-hour oral glucose tolerance test by using the oral glucose minimal model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beta-cell function</measure>
    <time_frame>8-weeks</time_frame>
    <description>To determine if the vitamin K-induced change in osteocalcin carboxylation effects beta-cell function in a dose-dependent manner. Beta-cell function, as assessed by dynamic beta-cell responsitivity, will be calculated from plasma glucose and C-peptide concentrations measured during a two-hour oral glucose tolerance test by using the oral C-peptide minimal model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in coagulation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Coagulation-related parameters (i.e., prothrombin time and activated partial thromboplastin time) will be assessed at baseline and 8 weeks to assess clotting function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arterial stiffness (pulse wave velocity)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Arterial stiffness, as measured by pulse wave velocity (PWV), will be assessed at baseline and 8 weeks to explore whether change in arterial stiffness is influenced by vitamin K2 supplementation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial function (flow-mediated dilation)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Endothelial function, as measured by flow-mediated dilation (FMD), will be assessed at baseline and 8 weeks to explore whether change in endothelial function is influenced by vitamin K2 supplementation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <condition>Obesity in Diabetes</condition>
  <condition>Nutritional and Metabolic Diseases</condition>
  <condition>Hyperlipidemia</condition>
  <condition>Hyperglycemia</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Placebo-Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo-control group will take two placebo softgel capsules every day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose Vitamin K2 (45-mcg/d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose Vitamin K2 (90-mcg/d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The high-dose vitamin K2 group will take two 45-mcg vitamin K2 softgel capsules every day for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo-Control</intervention_name>
    <description>two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)</description>
    <arm_group_label>Placebo-Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)</intervention_name>
    <description>one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks</description>
    <arm_group_label>Low-Dose Vitamin K2 (45-mcg/d)</arm_group_label>
    <other_name>menaquinone-7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)</intervention_name>
    <description>two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks</description>
    <arm_group_label>High-Dose Vitamin K2 (90-mcg/d)</arm_group_label>
    <other_name>menaquinone-7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 8 to 17 years

          -  Body mass index equal to or greater than 85th percentile for age and sex

          -  Subject and parent/guardian understands the study protocol and agrees to comply with
             it

          -  Informed Consent Form signed by the parent/guardian and assent signed by the subject

        Exclusion Criteria:

          -  Subjects using vitamin supplements containing vitamin k

          -  Subjects with (a history of) metabolic or gastrointestinal diseases including hepatic
             disorders

          -  Subjects presenting chronic degenerative and/or inflammatory diseases

          -  Subjects receiving systemic treatment or topical treatment likely to interfere with
             evaluation of the study parameters (salicylates, antibiotics)

          -  Subjects receiving corticosteroid treatment

          -  Subjects using oral anticoagulants

          -  Subjects with a history of soy allergy

          -  Subjects who have participated in a clinical study more recently than one month before
             the current study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman K Pollock, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Medical College of Georgia, Augusta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Norman K Pollock, PhD</last_name>
    <phone>706-721-5424</phone>
    <email>npollock@augusta.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Celestine Williams, MS</last_name>
    <phone>706-721-8553</phone>
    <email>cewilliams@augusta.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical College of Georgia; Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman K Pollock, Ph.D.</last_name>
      <phone>706-721-5424</phone>
      <email>npollock@augusta.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Douthit MK, Fain ME, Nguyen JT, Williams CF, Jasti AH, Gutin B, Pollock NK. Phylloquinone Intake Is Associated with Cardiac Structure and Function in Adolescents. J Nutr. 2017 Aug 9. pii: jn253666. doi: 10.3945/jn.117.253666. [Epub ahead of print]</citation>
    <PMID>28794209</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>March 25, 2018</last_update_submitted>
  <last_update_submitted_qc>March 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Norman Pollock</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>G01 [Biological Sciences]</keyword>
  <keyword>G02.513 [Nutrition]</keyword>
  <keyword>G06.696.259 [Child Nutrition]</keyword>
  <keyword>G07.553.481.398.571 [Obesity]</keyword>
  <keyword>G06 [Biochemical Phenomena, Metabolism, and Nutrition]</keyword>
  <keyword>G12.392.617 [Insulin Resistance]</keyword>
  <keyword>G06.696.259.500 [Adolescent Nutrition]</keyword>
  <keyword>A06 [Endocrine System]</keyword>
  <keyword>A07 [Cardiovascular System]</keyword>
  <keyword>C18.452.297.681 [Obesity in Diabetes]</keyword>
  <keyword>C18.452.555 [Insulin Resistance]</keyword>
  <keyword>C18 [Nutritional and Metabolic Diseases]</keyword>
  <keyword>C18.452.494 [Hyperlipidemia]</keyword>
  <keyword>C18.452.460 [Hyperglycemia]</keyword>
  <keyword>C14 [Cardiovascular Diseases]</keyword>
  <keyword>D11.786.875.844 [Vitamin K 2]</keyword>
  <keyword>D02.806.550.750 [Vitamin K 2]</keyword>
  <keyword>E02.293 [Diet Therapy]</keyword>
  <keyword>E02 [Therapeutics]</keyword>
  <keyword>F04.096.544.215.508.428 [Primary Prevention]</keyword>
  <keyword>N01.224.425.525 [Nutritional Status]</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Approximate date of when the data will be shared? 2019-06-28
Where will the data be made available? The de-identified data will be made available for research purposes only by contacting the principal investigator.
Please explain any limits to data sharing that might be required. Even though the final research data will be stripped of identifiers prior to release for sharing, the investigators believe that there remains the possibility of deductive disclosure of subjects with unusual characteristics. Thus, the investigators will make the data available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.augusta.edu/mcg/dphs/gpi/clinicalresearch.php</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

